Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by TechnicalBuyon Aug 05, 2011 1:06pm
418 Views
Post# 18908981

We're close to what could be a defining moment for

We're close to what could be a defining moment forI continue to accumulate. I was hoping that the latest pullback would give me a cheaper price but no luck. Looks like the word is getting out.

The Herceptin news has really spurred other pharmas to take a good look at BTI's technology. Not because they were interested in taking a piece of the $6bn Herceptin sales pie, but rather because they see potential for a scientific breakthrough in the fight against central nervouse system diseases.

I mentioned this in my BTI article before, crossing the blood brain barrier is the holy grail of the CNS research. Many pharmas have spent a lot of money on BBB research, namely because the payout would be fantastic. This is a $100bn market. What Bioasis has is in a way invaluable. If it works out we could be looking at $100s of millions in annual revenue from licensing agreements.

In-vivo results for Herceptin will be very interesting and could be a defining moment for Bioasis. Only weeks away...

TB
Bullboard Posts